Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Diffuse intrinsic pontine glioma (DIPG): time to biopsy again?

MacDonald TJ.

Pediatr Blood Cancer. 2012 Apr;58(4):487-8. doi: 10.1002/pbc.24090. No abstract available.

PMID:
22331797
2.

Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma.

Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L, Kieran MW.

Pediatr Blood Cancer. 2012 Apr;58(4):489-91. doi: 10.1002/pbc.24060. Epub 2011 Dec 20.

PMID:
22190243
3.

Molecular genetic approaches and potential new therapeutic strategies for pediatric diffuse intrinsic pontine glioma.

Hawkins CE, Bartels U, Bouffet E.

J Clin Oncol. 2011 Oct 20;29(30):3956-7. doi: 10.1200/JCO.2011.37.8661. Epub 2011 Sep 19. No abstract available.

PMID:
21931033
4.

Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment.

Trbusek M, Malcikova J, Smardova J, Kuhrova V, Mentzlova D, Francova H, Bukovska S, Svitakova M, Kuglik P, Linkova V, Doubek M, Brychtova Y, Zacal J, Kujickova J, Pospisilova S, Dvorakova D, Vorlicek J, Mayer J.

Leukemia. 2006 Jun;20(6):1159-61. No abstract available.

PMID:
16572201
5.

Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model.

Caretti V, Zondervan I, Meijer DH, Idema S, Vos W, Hamans B, Bugiani M, Hulleman E, Wesseling P, Vandertop WP, Noske DP, Kaspers G, Molthoff CF, Wurdinger T.

Brain Pathol. 2011 Jul;21(4):441-51. doi: 10.1111/j.1750-3639.2010.00468.x. Epub 2010 Dec 29.

PMID:
21159008
6.

Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'.

Pander J, Gelderblom H, van der Straaten T, Punt CJ, Guchelaar HJ.

Br J Cancer. 2010 Jun 8;102(12):1791-2. doi: 10.1038/sj.bjc.6605709. No abstract available.

7.

Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma.

Malmer BS, Feychting M, Lönn S, Lindström S, Grönberg H, Ahlbom A, Schwartzbaum J, Auvinen A, Collatz-Christensen H, Johansen C, Kiuru A, Mudie N, Salminen T, Schoemaker MJ, Swerdlow AJ, Henriksson R.

J Neurooncol. 2007 May;82(3):229-37. Epub 2006 Dec 7.

PMID:
17151932
8.

May a missense mutation be more deleterious than a truncating mutation?

di Masi A.

IUBMB Life. 2008 Jan;60(1):79-81. doi: 10.1002/iub.2. No abstract available.

9.

Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.

Carter A, Lin K, Sherrington PD, Atherton M, Pearson K, Douglas A, Burford A, Brito-Babapulle V, Matutes E, Catovsky D, Pettitt AR.

Leukemia. 2006 Apr;20(4):737-40. No abstract available.

PMID:
16437137
10.

Contralateral second breast cancers: prediction and prevention.

Brenner DJ.

J Natl Cancer Inst. 2010 Apr 7;102(7):444-5. doi: 10.1093/jnci/djq058. Epub 2010 Mar 19. No abstract available.

PMID:
20305130
11.

Gene linked to pancreatic cancer.

Fillon M.

J Natl Cancer Inst. 2012 Mar 21;104(6):438-9. doi: 10.1093/jnci/djs173. Epub 2012 Mar 5. No abstract available.

PMID:
22393211
12.

ATM targets hnRNPK to control p53.

Blasius M, Bartek J.

Cell Cycle. 2013 Apr 15;12(8):1162-3. doi: 10.4161/cc.24485. Epub 2013 Apr 2. No abstract available.

13.

Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors.

Kheirollahi M, Mehr-Azin M, Kamalian N, Mehdipour P.

Med Oncol. 2011 Mar;28(1):7-14. doi: 10.1007/s12032-009-9412-8. Epub 2010 Jan 14.

PMID:
20077038
14.

Fine-tuning the p53 response to DNA damage: a new piece in the puzzle.

Polo SE.

Cell Cycle. 2013 May 1;12(9):1337-8. doi: 10.4161/cc.24669. Epub 2013 Apr 15. No abstract available.

15.

Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG.

Bartels U, Hawkins C, Vézina G, Kun L, Souweidane M, Bouffet E.

J Neurooncol. 2011 Oct;105(1):119-25. doi: 10.1007/s11060-011-0704-4. Epub 2011 Sep 8.

PMID:
21901544
16.

Homozygosity for c 6325T>G transition in the ATM gene causes an atypical, late-onset variant form of ataxia-telangiectasia.

Silvestri G, Masciullo M, Piane M, Savio C, Modoni A, Santoro M, Chessa L.

J Neurol. 2010 Oct;257(10):1738-40. doi: 10.1007/s00415-010-5583-7. Epub 2010 May 18. No abstract available.

PMID:
20480175
17.

E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.

Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG.

Mol Cancer Res. 2004 Apr;2(4):203-14.

18.

Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China.

Cao AY, Hu Z, Shao ZM.

Breast Cancer Res Treat. 2010 Feb;120(1):271-2. doi: 10.1007/s10549-009-0598-4. Epub 2009 Oct 24. No abstract available.

PMID:
19856097
19.

Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis.

Loehberg CR, Thompson T, Kastan MB, Maclean KH, Edwards DG, Kittrell FS, Medina D, Conneely OM, O'Malley BW.

Cancer Res. 2007 Dec 15;67(24):12026-33.

20.

Human tumor cells segregate into radiosensitivity groups that associate with ATM and TP53 status.

Williams JR, Zhang Y, Russell J, Koch C, Little JB.

Acta Oncol. 2007;46(5):628-38.

PMID:
17562439

Supplemental Content

Support Center